RECRUITINGOBSERVATIONAL
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data
About This Trial
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Who May Be Eligible (Plain English)
Who May Qualify:
- Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
- Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
- Is concomitantly on one or more prescription medications or illicit drugs.
Who Should NOT Join This Trial:
- Treated with DAAs other than G/P.
- History of decompensated cirrhosis.
- Had Hepatitis-B virus (HBV) infection.
- Had hepatocellular carcinoma (HCC).
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
* Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
* Is concomitantly on one or more prescription medications or illicit drugs.
Exclusion Criteria:
* Treated with DAAs other than G/P.
* History of decompensated cirrhosis.
* Had Hepatitis-B virus (HBV) infection.
* Had hepatocellular carcinoma (HCC).
Locations (2)
Vancouver Infectious Diseases Centre /ID# 275313
Vancouver, British Columbia, Canada
St. Clair Medical Clinic /ID# 275334
Toronto, Ontario, Canada